Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy

Annals of Pharmacotherapy

Volumn 43, Issue 7-8, 2009, Pages 1360-1365

  Mueller, Scott W ^a   MacLaren, Robert ^a   Fish, Douglas N ^b   Kiser, Tyree H ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Anticoagulation; Bivalirudin; Bleeding; CRRT; Dialysis; Direct thrombin inhibitor; Hemofilter; Hirulog; Platelet; Thrombus

Indexed keywords

HEPARIN; HIRULOG; PHYTOMENADIONE;

ACUTE KIDNEY FAILURE; ADULT; ANAMNESIS; ANTICOAGULATION; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY FUNCTION; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SEROTONIN RELEASE;

ADULT; ANTICOAGULANTS; HEMOFILTRATION; HEPARIN; HIRUDINS; HUMANS; KIDNEY FAILURE, ACUTE; MALE; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 67651097801     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M179     Document Type: Article

References (30)

1. Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 2006;32:188-202.
2. Package insert. Refludan (lepirudin). Wayne, NJ: Bayer HealthCare Pharmceuticals, manufactured by CSL Behring GmbH, December 2006.
3. Package insert. Argatroban. Houston, TX: Encysive Pharmaceuticals, Inc., manufactured by GlaxoSmithKline, May 2008.
4. Package insert. Angiomax (bivalirudin). Parsippany, NJ: BenVenue Laboratories, December 2005.
5. Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother 2005;6:1349-1371
6. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008;99:830-839
7. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002;71:433-439 (Pubitemid 34701350)
8. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000;12(suppl F):33F-6.
9. Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968;28:14-20.
10. Hunt WE, Meagher JN, Hess RM. Intracranial aneurysm. A nine-year study. Ohio State Med J 1966;62:1168-1171
11. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1-9.
12. Bellomo R, Kellum JA, Mehta R, Palevsky PM, Ronco C. Acute Dialysis Quality Initiative II: the Vicenza conference. Curr Opin Crit Care 2002;8:505-508
13. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-12.
14. Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006;10:R73. (Pubitemid 47086852)
15. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649
16. Davenport A. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis 1997;30(5 suppl 4):S20-7. (Pubitemid 27465336)
17. Stefanidis I, Frank D, Maurin N. Hemostasis activation markers in acute renal failure. Ren Fail 1998;20:147-155 (Pubitemid 28087841)
18. Colucci M, Balconi G, Lorenzet R, et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71:1893-1896
19. Cardigan RA, McGloin H, Mackie IJ, Machin SJ, Singer M. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int 1999;55:1568-1574 (Pubitemid 29157158)
20. Bastien O, French P, Paulus S, et al. Antithrombin III deficiency during continuous venovenous hemodialysis. Contrib Nephrol 1995;116:154-158
21. Kappelmayer J, Bernabei A, Edmunds LH Jr, Edgington TS, Colman RW. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 1993;72:1075-1081 (Pubitemid 23105512)
22. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996;7:145-150 (Pubitemid 26067101)
23. Vargas Hein O, von Heymann C, Lipps M, et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med 2001;27:673-679 (Pubitemid 32304571)
24. Koster A, Hentschel T, Groman T, et al. Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. J Thorac Cardiovasc Surg 2007; 133:1376-1377 (Pubitemid 46656385)
25. Hein OV, von Heymann C, Diehl T, et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Ren Fail 2004;26:297-303. (Pubitemid 39050672)
26. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparininduced thrombocytopenia with hepatic dysfunction. Chest 2006;129: 1167-1175 (Pubitemid 44857777)
27. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-329
28. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006;26:452-460
29. Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2008;28:1115-1124
30. Mann MJ, Tseng E, Ratcliffe M, et al. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia. J Heart Lung Transplant 2005;24:222-225 (Pubitemid 40215601)